Iovance Biotherapeutics (IOVA) Stock Analysis

What Iovance Biotherapeutics does

Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.

Key metrics

ETFs linked to IOVA

Broad-market and Healthcare sector ETFs an investor holding Iovance Biotherapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how IOVA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Iovance Biotherapeutics?

Iovance Biotherapeutics trades under the ticker IOVA on NASDAQ.

Which exchange is IOVA listed on?

IOVA is listed on NASDAQ.

What sector does Iovance Biotherapeutics operate in?

Iovance Biotherapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze IOVA in a portfolio?

PortView shows IOVA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.